Latham & Watkins has advised Novo Holdings as the co-lead investor in the Series E Preferred Stock financing round for Quanta Dialysis Technologies, a leader in transforming kidney care through its award-winning Quanta™ Dialysis System, raising more than US$60 million of additional capital.
Led by Novo Holdings, Glenview Capital, and b2venture, with broad participation by existing shareholders, the latest funding round underscores strong investor confidence in Quanta’s market potential to revolutionize the treatment of kidney disease across a variety of settings. With the newly secured capital, Quanta will expand its commercial presence in the US and continue to invest in cutting-edge innovation within the sector.
The Latham team was led by London corporate partner Robbie McLaren, with associates Samantha Peacock and Richard Dodding.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
